MONROVIA, Calif., Nov. 9, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that data results from a Phase 1b/2a study of XmAb®5871 in patients with rheumatoid arthritis (RA) are being presented during an oral presentation today, Monday, November 9, 2015 at the American College of Rheumatology (ACR) 2015 Annual Meeting in San Francisco, California. Complete data results on the Phase 1b/2a RA study were previously announced at the European League Against Rheumatism (EULAR) 2015 Annual Meeting in Rome in...
↧